Aclidinium Bromide Inhalation Powder Labeling Updated With Data Related to COPD With CV Comorbidity
The Food and Drug Administration (FDA) has approved the inclusion of new data from the ASCENT trial in the prescribing information for Tudorza Pressair (aclidinium bromide inhalation powder; Circassia), an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). In ASCENT, the effect of Tudorza on major adverse cardiovascular events…
